Honokiol in glioblastoma recurrence: a case report

Ce Wang; Zehao Cai; Yue Huang; Xinrui Liu; Xing Liu; Feng Chen; Wenbin Li

doi:10.3389/fneur.2023.1172860

Honokiol in glioblastoma recurrence: a case report

Front Neurol. 2023 Jun 22:14:1172860. doi: 10.3389/fneur.2023.1172860. eCollection 2023.

Authors

Ce Wang^#¹, Zehao Cai^#¹, Yue Huang², Xinrui Liu¹, Xing Liu³, Feng Chen¹, Wenbin Li¹

Affiliations

¹ Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
² Human Brain and Tissue Bank, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
³ Department of Neuropathology, Beijing Neurosurgical Institute, Beijing, China.

^# Contributed equally.

Abstract

Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes. We report an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma.

Keywords: blood–brain barrier permeability; clinical trial; glioblastoma; liposomal honokiol; tumor progression.

Publication types

Case Reports

Grants and funding

This research was funded by the National Natural Science Foundation of China, grant number: 81972338. This research was also funded by the Beijing Municipal Natural Science Foundation, grant number: J200003.